Research on the combined impact of high-flux dialysis and levocarnitine on the functionality of arteriovenous fistulas in patients undergoing maintenance hemodialysis.

To explore the influence of levocarnitine on arteriovenous fistula (AVF) function in patients undergoing high-flux dialysis and delve into its potential mechanisms. Complication Reduction: The treatment group had markedly lower incidences of vascular stenosis (4.69% vs. 20%), thrombosis (3.13% vs. 15%), poor venous return (6.25% vs. 18.33%), and pre-dialysis hypotension (7.81% vs. 23.33%) (all P < 0.05). Hematological Benefits: Significant improvements in hemoglobin (11.57 ± 1.63 vs. 10.38 ± 1.49g/dL) and red blood cell count (3.89 ± 0.51 vs. 3.53 ± 0.46 ×10¹²/L) were observed in the treatment group (P < 0.001), alongside reduced white blood cell counts (6.05 ± 1.49 vs. 6.23 ± 1.60 ×109/L, P = 0.006). Quality of Life: Karnofsky Performance Scale (KPS) scores were significantly higher in the treatment group at both 1-month (P < 0.01) and 3-month follow-ups (P < 0.01). In the context of high-flux hemodialysis, supplementing with levocarnitine can appreciably improve AVF function in ESRD patients, mitigate the occurrence of complications, and potentially enhance the quality of life by alleviating dialysis-related issues. Levocarnitine emerges as a promising adjunctive therapy for patients with compromised AVF function.